Table 1A.
Demographic and Baseline Characteristics (Abacavir/Lamivudine vs. Tenofovir/Emtricitabine)
| |
Abacavir/lamivudine |
Tenofovir/emtricitabine |
|
||
|---|---|---|---|---|---|
| (n=54) | (n=143) | p-value | |||
| Age, years [median (IQR)] | 46.5 | (42–56) | 44 | (40–48) | 0.0054 |
| Female sex [n (%)] | 10 | (18.52) | 27 | (25.87) | 0.48 |
| Ritonavir-boosted protease inhibitors at entry [n (%)] | |||||
| Lopinavir/ritonavir | 25 | (46.3) | 68 | (47.55) | |
| Atazanavir/ritonavir | 20 | (37.04) | 47 | (32.87) | |
| Fosamprenavir/ritonavir | 9 | (16.67) | 14 | (9.79) | |
| Saquinavir/ritonavir | — | (0) | 2 | (1.4) | |
| Darunavir/ritonavir | — | (0) | 1 | (0.7) | |
| Tipranavir/ritonavir | — | (0) | 1 | (0.7) | |
| Patients on their first antiretroviral regimen [n (%)] | 9 | (16.67) | 18 | (12.59) | 0.48 |
| Exposure to antiretroviral therapy (years) [median (range)] | 9.17 | (4–11.77) | 10.13 | (3.7–12.76) | 0.56 |
| Exposure to protease inhibitor-based therapy (months) [median (range)] | 28 | (15.52–44.03) | 29.22 | (18.53–36.23) | 0.92 |
| Patients with previous suboptimal antiretroviral therapy [n (%)] | 15 | (27.78) | 55 | (38.46) | 0.18 |
| Patients with previous virological failure [n (%)] | 7 | (12.96) | 54 | (37.76) | <0.001 |
| Patients with previous suboptimal antiretroviral therapy or virological failure [n (%)] | 19 | (35.19) | 70 | (48.95) | 0.10 |
| Number of previous antiretroviral regimens [median (IQR)] | 4 | (2–7) | 5 | (2–7.5) | 0.71 |
| Number of previous suboptimal antiretroviral regimens [median (IQR)] | 2 | (1–2) | 2 | (1–3) | 0.41 |
| Number of previous virological failures [median (IQR)] | 2 | (1–2) | 1 | (1–3) | 0.86 |
| Patients with AIDS [n (%)] | 25 | (0.7) | 71 | 50 | 0.75 |
| CD4 cell count (cells/ml) [median (IQR)] | 514.5 | (375.15–779.7) | 486.5 | (355.5–720) | 0.52 |
| CD8 cell count (cells/ml) [median (IQR)] | 761.91 | (577.98–1085.76) | 799 | (575–1071.33) | 0.946 |
| Triglycerides (mg/dl) [median (IQR)] | 193 | (150.58–268) | 153.5 | (103–238) | 0.007 |
| Triglycerides >200 mg/dl [n (%)] | 23 | (42.59) | 48 | (33.57) | 0.24 |
| Total cholesterol (mg/dl) [median (IQR)] | 219.3 | (193–242) | 193.5 | (167.5–221) | 0.001 |
| Total cholesterol >240 mg/dl [n (%)] | 14 | (25.93) | 17 | (11.89) | 0.026 |
| LDL cholesterol (mg/dl) [median (IQR)] | 129.5 | (107.25–149.25) | 119 | (96–146) | 0.20 |
| LDL cholesterol >160 mg/dl [n (%)] | 16.67 | (54) | 11.19 | (143) | 0.33 |
| HDL cholesterol (mg/dl) [median (IQR)] | 49.62 | (38.85–57.31) | 42.31 | (34–52.7) | 0.008 |
| HDL cholesterol <40 mg/dl [n (%)] | 15 | (27.78) | 55 | (38.46) | 0.18 |
| Lipid-lowering therapy at entry [n (%)] | 14 | (25.93) | 19 | (13.29) | 0.052 |